This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 Jan;28(1):6-7.

doi: 10.1038/s41591-021-01594-1.

The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension

Christina Yap¹, Alun Bedding², Johann de Bono³, Munyaradzi Dimairo⁴, Aude Espinasse³, Jeffry Evans⁵, Sally Hopewell⁶, Thomas Jaki^{7

8}, Andrew Kightley⁹, Shing Lee¹⁰, Rong Liu¹¹, Adrian Mander¹², Olga Solovyeva³, Christopher J Weir¹³

Affiliations

Affiliations

¹ Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK. christina.yap@icr.ac.uk.
² Roche, Welwyn Garden City, UK.
³ Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK.
⁴ School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.
⁵ University of Glasgow, Glasgow, UK.
⁶ University of Oxford, Oxford, UK.
⁷ Lancaster University, Lancaster, UK.
⁸ University of Cambridge, Cambridge, UK.
⁹ Patient and Public involvement partner, Lichfield, Staffordshire, UK.
¹⁰ Columbia University, New York, NY, USA.
¹¹ Bristol Meyers Squibb, Berkeley Heights, New Jersey, USA.
¹² Centre for Trials Research, Cardiff University, Cardiff, UK.
¹³ Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.

PMID: 34992264
DOI: 10.1038/s41591-021-01594-1

The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension

Christina Yap et al. Nat Med. 2022 Jan.

. 2022 Jan;28(1):6-7.

doi: 10.1038/s41591-021-01594-1.

Authors

Christina Yap¹, Alun Bedding², Johann de Bono³, Munyaradzi Dimairo⁴, Aude Espinasse³, Jeffry Evans⁵, Sally Hopewell⁶, Thomas Jaki^{7

8}, Andrew Kightley⁹, Shing Lee¹⁰, Rong Liu¹¹, Adrian Mander¹², Olga Solovyeva³, Christopher J Weir¹³

Affiliations

¹ Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK. christina.yap@icr.ac.uk.
² Roche, Welwyn Garden City, UK.
³ Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK.
⁴ School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.
⁵ University of Glasgow, Glasgow, UK.
⁶ University of Oxford, Oxford, UK.
⁷ Lancaster University, Lancaster, UK.
⁸ University of Cambridge, Cambridge, UK.
⁹ Patient and Public involvement partner, Lichfield, Staffordshire, UK.
¹⁰ Columbia University, New York, NY, USA.
¹¹ Bristol Meyers Squibb, Berkeley Heights, New Jersey, USA.
¹² Centre for Trials Research, Cardiff University, Cardiff, UK.
¹³ Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.

PMID: 34992264
DOI: 10.1038/s41591-021-01594-1

No abstract available

PubMed Disclaimer

References

1. Aitken, M. Global trends in clinical research. PharmaTimes https://www.pharmatimes.com/magazine/2021/julyaugust_2021/global_trends_... (July 2021).
1. Wong, C. H. et al. Biostatistics 20, 273–286 (2019). - DOI
1. Dowden, H. & Munro, J. Nat. Rev. Drug Discov. 18, 495–496 (2019). - DOI
1. Mariani, L. & Marubini, E. J. Clin. Oncol. 18, 429–436 (2000). - DOI
1. Rogatko, A. et al. J. Clin. Oncol. 25, 4982–4986 (2007). - DOI

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Nature Publishing Group